<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147403</url>
  </required_header>
  <id_info>
    <org_study_id>ETMEFP_LYB_2019</org_study_id>
    <nct_id>NCT04147403</nct_id>
  </id_info>
  <brief_title>A Study of Extended Total Mesopancreas Excision(eTME) for Pancreatic Head Adenocarcinoma.</brief_title>
  <official_title>Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study of extended total mesopancreas excision(eTME) for pancreatic head adenocarcinoma is
      a retrospective multicenter cohort, collecting medical records and follow-up data of patients
      who underwent radical resection with pancreatic head adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study are as follows:

        1. To evaluate the perioperative safety of extended total mesopancreas excision(eTME) for
           patients who diagnosed with resectable pancreatic head adenocarcinoma.

        2. To demonstrate the prognosis of extended total mesopancreas excision(eTME) for patients
           who diagnosed with resectable pancreatic head adenocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2008</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>The overall survival data were defined by (date of death)-(date of first diagnosis).The survival status of patients were retrieved from follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>The overall survival data were defined by (date of recurrence/progression)-(date of surgery).During follow-up period, abdominal enhanced CT, chest X-ray, tumor markers and routine blood tests were carried out to evaluate recurrence/progression.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pancreas Adenocarcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with resectable pancreatic head adenocarcinoma who underwent radical resection
        between January 1st 2008 and October 31st 2018 in collaborated tertiary hospital hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with pancreatic head adenocarcinoma who underwent curative-intent resection.

          2. Patients with accessible medical records

        Exclusion Criteria:

          1. Patients with unknown chemotherapy sequence or status

          2. Patients with history of previous malignant tumors

          3. Patients with distant metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingbin Liu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingbin Liu, Ph.D.</last_name>
    <phone>+8613918803900</phone>
    <email>laoniulyb@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital,Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boyong Shen, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenhui Lou, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital Affiliated to Naval Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Jin, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingbin Liu, Ph.D.</last_name>
      <phone>+8613918803900</phone>
      <email>laoniulyb@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Yingbin Liu, MD, PhD, FACS</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>pancreatic head adenocarcinoma; total mesopancreas excision;pancreaticoduodenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

